CORRECTING AND REPLACING Data from the Phase III SATURN Study Show Tarceva Improved Progression-Free Survival When Used as a ...

Eighth graph, third sentence should read: Fifty-five percent of patients in the Tarceva arm and 64% of patients on placebo received subsequent therapy after progressing. (sted Sixty-four percent of patients in the Tarceva arm and 55% of patients on placebo received subsequent therapy after progressing.)

The corrected release reads:

DATA FROM THE PHASE III SATURN STUDY SHOW TARCEVA IMPROVED PROGRESSION-FREE SURVIVAL WHEN USED AS A FIRST-LINE MAINTENANCE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER

-- Data Showed Tarceva Improved PFS in Patients with Both Non-Squamous Cell Carcinoma and Squamous Cell Carcinoma --

-- Patients with an EGFR Mutation Achieved a 10 Fold Increase in the Time Patients Live Without Their Disease Worsening –

-- Biomarker Data Suggest K-ras Mutation Status is not a Predictor of Efficacy in NSCLC Patients Treated with Tarceva --

OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced detailed results from the Phase III SATURN study of Tarceva® (erlotinib) as a single agent, first-line maintenance therapy for patients with advanced non-small cell lung cancer (NSCLC) who did not progress following first-line treatment with platinum-based chemotherapy. The study met both of its co-primary endpoints by demonstrating a statistically significant 41% improvement in the time patients live without their disease worsening (as measured by progression free survival, or PFS) compared with placebo (Hazard Ratio = 0.71, p-value